Absci Corp

Overview

Compare with iSpecimen Inc., VITASPRING BIOMEDICAL CO. LTD. or OneMedNet Corp, or pick any stock.

• TickerABSI on Nasdaq¹
• IndustryServices-Commercial Physical & Biological Research¹
• HeadquartersVancouver, Washington¹
• Business address18105 Se Mill Plain Blvd, Vancouver, Wa 98683²
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop. We focus on underexplored mechanisms where unmet medical need is high and competition is low.⁴ From its latest annual report

Corporate structure

Absci Corp sits at the top of its group. 4 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Absci Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

Our corporate headquarters and primary research and development facilities are located in Vancouver, Washington in a 77,974 square foot facility that includes general administrative office and laboratory space. Our AI Research Lab is located in New York, New York and our Innovation Center is located in Zug, Switzerland. Additionally, we have research and development presence in Belgrade, Serbia. Substantially all of our office space is leased with varying expiration dates. We believe our facilities are adequate and suitable for our current and near future needs.

Item 2 of the 10-K filed Mar 24, 2026.⁴

Leadership

Who has led Absci Corp, and when. Pick a name to see everywhere that person has worked.

• Chief financial officerZachariah Jonasson Sep 6, 2023 to now¹²
• Chief financial officerGregory T. Schiffman Jul 21, 2021 to Mar 3, 2023¹³
• Chief operating officerAndreas Pihl Jul 21, 2021 to Jul 28, 2021¹⁴

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• AbSci, LLC Delaware³
• Absci GmbH Switzerland³
• Absci Pty Ltd Australia³
• Absci d.o.o. Beograd Serbia³
• De Novo Design, LLC Delaware³
• Target Discovery Merger Sub II, LLC Delaware³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• AbSci, LLCApr 21, 2016 to Dec 19, 2019²

Timeline

1. Aug 11, 20268-K Results of operations; Other events³³
2. Jun 24, 20268-K Other events³⁴
3. Jun 24, 20268-K Entered a material agreement; Other events³⁵
4. Jun 5, 20268-K Shareholder vote³⁶
5. May 7, 20268-K Results of operations; Other events³⁷
6. Mar 24, 20268-K Results of operations; Other events³⁸
7. Mar 6, 20268-K Entered a material agreement; Executive or director change; Regulation FD disclosure³⁹
8. Jan 14, 20268-K Other events⁴⁰
9. Nov 12, 20258-K Results of operations; Other events⁴¹
10. Nov 4, 20258-K Entered a material agreement⁴²
11. Aug 12, 20258-K Results of operations; Other events⁴³
12. Aug 12, 20258-K Results of operations; Other events⁴⁴

Calendar

Coming up

1. Nov 12, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported ($0.20) a share, on Nov 12, 2025.⁴⁵

When it reported results

1. Aug 11, 2026Reported quarterly or annual results³³
2. May 7, 2026Reported quarterly or annual results³⁷
3. Mar 24, 2026Reported quarterly or annual results³⁸
4. Nov 12, 2025Reported quarterly or annual results⁴¹
5. Aug 12, 2025Reported quarterly or annual results⁴³
6. Aug 12, 2025Reported quarterly or annual results⁴⁴
7. May 13, 2025Reported quarterly or annual results⁴⁶
8. Mar 18, 2025Reported quarterly or annual results⁴⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

294 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 54 major events, 137 insider forms, 38 large holders, 44 other. The latest 20:

1. Oct 14, 20264 EDGAR
2. Oct 14, 20264 EDGAR
3. Oct 14, 20264 EDGAR
4. Sep 1, 20264 EDGAR
5. Aug 11, 202610-Q EDGAR
6. Aug 11, 20268-K EDGAR
7. Aug 7, 20264 EDGAR
8. Aug 7, 20263 EDGAR
9. Jul 6, 20264 EDGAR
10. Jun 26, 20264 EDGAR
11. Jun 24, 20268-K EDGAR
12. Jun 24, 20268-K EDGAR
13. Jun 24, 2026424B5 EDGAR
14. Jun 15, 20264/A EDGAR
15. Jun 11, 20264 EDGAR
16. Jun 8, 20264 EDGAR
17. Jun 8, 20264 EDGAR
18. Jun 8, 20264 EDGAR
19. Jun 8, 20264 EDGAR
20. Jun 8, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 12 buys and 11 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Redmile Group, LLCSCHEDULE 13D/A, 4 filings Mar 5, 2024 to Apr 14, 2026⁴⁸
• VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Jul 29, 2025 to Mar 26, 2026⁴⁹
• Sean McClainSCHEDULE 13G/A, 5 filings Feb 11, 2022 to Nov 13, 2025⁵⁰
• BlackRockSCHEDULE 13G/A, 3 filings Oct 18, 2024 to Jul 16, 2025⁵¹
• ALGER ASSOCIATES INCSCHEDULE 13G/A, 3 filings Nov 14, 2024 to May 15, 2025⁵²
• Phoenix Venture Partners II LPSCHEDULE 13G/A, 5 filings Feb 14, 2022 to May 15, 2025⁵³
• ARK Investment Management LLCSCHEDULE 13G/A, 3 filings Jan 10, 2025 to May 14, 2025⁵⁴
• FMR LLCSCHEDULE 13G/A, 6 filings Oct 12, 2021 to May 12, 2025⁵⁵
• Casdin Capital, LLCSC 13D/A, 4 filings Jul 21, 2022 to May 8, 2023⁵⁶
• Mark ValasekSC 13G, 1 filing Feb 14, 2022⁵⁷

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Absci Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARAbsci Corp¹
• CIK0001672688
• Employer ID (EIN)85-3383487⁴
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)8731 Services-Commercial Physical & Biological Research¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address18105 Se Mill Plain Blvd, Vancouver, WA 98683¹
• Phone(360) 949-1041¹
• Shares outstanding171,614,010 as of Jul 31, 2026¹¹
• Public float$303.8M as of Jun 30, 2025⁴
• AuditorErnst & Young LLP, San Jose, California PCAOB ID 42; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceApr 21, 2016¹
• Filings358 in all: 4 (131), 8-K (56), 3 (23), 10-Q (16), SCHEDULE 13G/A (12), CORRESP (10), UPLOAD (9), 4/A (8)¹
  All 39 form types

  SC 13G (8), SC 13G/A (7), 424B5 (6), S-8 (6), 10-K (5), D (5), DEF 14A (5), DEFA14A (5), SC 13D/A (5), ARS (4), EFFECT (4), S-1/A (4), S-3 (3), SCHEDULE 13D/A (3), SCHEDULE 13G (3), 424B3 (2), D/A (2), SC 13D (2), SEC STAFF LETTER (2), 10-K/A (1), 144 (1), 424B4 (1), 5 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), PRE 14A (1), S-1 (1)

• Latest filingsAnnual report (10-K) Mar 24, 2026
  Quarterly report (10-Q) Aug 11, 2026
  Proxy statement (DEF 14A) Apr 22, 2026
  Latest 8-K (8-K) Aug 11, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 24, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Absci Corp names in Item 1A of its 10-K filed Mar 24, 2026: 72 risks under these headings, as written.⁴

• Risks Related to Our Financial Condition and Need for Additional Capital
• Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
• We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.
• We will need to raise additional capital to fund our operations, pre-clinical and clinical development of our internally developed programs, and to improve our Integrated Drug Creation platform. If we are unable to raise additional capital on terms acceptable to us or at all, we may not be able to continue to develop our internally developed programs and/or compete successfully with our Integrated Drug Creation platform, which would harm our business, operations, and financial condition.
• Substantially all of our historical revenue is related to partnered drug creation activities, and we have not demonstrated the ability to enter into a sufficient number of partnerships providing for long-term license arrangements under which we are entitled to receive milestone payments or royalties on net product sales. We have not received any such milestone or royalty revenues to date, and it may be years before we realize any such revenues, if at all.
• Risks Related to Biologic Drug Development
• Biologic drug development is inherently uncertain, and it is possible that our technology may not succeed in discovering appropriate product candidates. Even if we do succeed, it is possible that none of the product candidates created using our Integrated Drug Creation platform, if any, that are further developed by our partners will achieve development or regulatory milestones, including marketing approval, or become viable commercial technologies, on a timely basis or at all, which would harm our ability to generate revenue.
• Positive results from early preclinical studies or preliminary results from clinical trials of our product candidates are not necessarily predictive of the results of later preclinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive results from our earlier preclinical studies of our product candidates in our later preclinical studies, clinical trials and future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.
• Preclinical and clinical development is uncertain. Our or our partners' preclinical and clinical product candidates may experience delays or may never advance to and/or through clinical trials, which would adversely affect our or our partners’ ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.
• If we or our partners experience any of a number of possible unforeseen or negative events in connection with preclinical or clinical development, regulatory approval or commercialization of product candidates generated through our platform, this could negatively affect our revenue
• opportunity for that program, and/or have broader deleterious effects on our reputation and future partnership prospects.
• Preliminary data and interim results we disclose from our clinical trials may change as more data becomes available or as we make changes to our clinical protocols or processes, and such interim results or results from earlier studies may not be predictive of the final results, or of later studies or future clinical trials.

Legal proceedings

We are not currently a party to any material litigation or other legal proceedings. From time to time, we may, however, in the ordinary course of business face various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights. Any such claims and associated legal proceedings could, in the opinion of our management, have a material adverse effect on our business, financial condition, results of operations or prospects. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.⁴